Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that ...

VHH antibodies, they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But ...

The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges. The ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...

Hims said it “deciding to stop offering access” to the treatment following escalating legal threats — among them a patent infringement suit Novo Nordisk filed against the company on Monday.

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...